Table 1.
Baseline Characteristics
| DCM (n=24) | ICM (n=43) | P Value | |
|---|---|---|---|
| Age at cell delivery, y | 55.4±12.1 | 61.4±10.0 | 0.04 |
| Treatment cell type | 0.02 | ||
| Autologous | 9 (37.5%) | 29 (67.4%) | |
| Allogeneic | 15 (62.5%) | 14 (32.6%) | |
| Sex | 0.05 | ||
| Male | 16 (66.7%) | 38 (88.4%) | |
| Female | 8 (33.3%) | 5 (11.6%) | |
| AICD or BIV/CRT | 19 (79.2%) | 26 (60.5%) | 0.17 |
| Ethnicity: Hispanic or Latino | 9 (37.5%) | 12 (27.9%) | 0.43 |
| Race: White | 16 (66.7%) | 12 (27.9%) | 0.004 |
| History of hypertension | 8 (33.3%) | 23 (53.5%) | 0.13 |
| History of atrial or ventricular arrhythmia | 4 (16.7%) | 25 (58.1%) | 0.002 |
| History of hyperlipidemia | 5 (20.8%) | 35 (81.4%) | 0.0001 |
| History of smoking | 15 (62.5%) | 21 (48.8%) | 0.32 |
| History of diabetes mellitus | 1 (4.2%) | 9 (20.9%) | 0.08 |
| NYHA Class | 0.53 | ||
| Class I‐no limitation | 9 (28.1%) | 9 (19.6%) | |
| Class II‐slight limitation of physical activity | 16 (50.0%) | 26 (58.7%) | |
| Class III‐marked limitation of physical activity | 7 (21.9%) | 11 (23.9%) | |
| 6‐minute walk test, m | 439.8±92.6 | 389.6±86.1 | 0.03 |
| MLHFQ | 36.75±24.65 | 35.46±29 | 0.66 |
| LV size and function | |||
| Ejection fraction, % | 27.0±10.1 | 30.7±10.5 | 0.17 |
| Stroke volume, mL | 84.3±27.24 | 80.5±25.6 | |
| LV end‐diastolic volume, mL | 299.9 (257.0, 421.0) | 270 (206.0, 330.0) | 0.09 |
| LV end‐systolic volume, mL | 232.8 (170.3, 319.0) | 187 (128.0, 251.0) | 0.09 |
| Sphericity index | 0.53±0.1 | 0.48±.0.1 | 0.08 |
| End‐diastolic mass, g | 203.3 (170.8, 307.8) | 212.5 (178.6, 248.2) | 0.97 |
Values are n (%), mean±SD, or median (interquartile range). AICD indicates the automated cardioverter‐defibrillator; BIV/CRT, biventricular pacemaker/cardiac resynchronization therapy; DCM, dilated cardiomyopathy; ICM, ischemic cardiomyopathy; LV, left ventricular; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NYHA, New York Heart Association.